Autonomix Stock Surges 49% on Breakthrough Nerve-Mapping PoC Data
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Autonomix Medical Inc (NASDAQ: AMIX; name in Korean: 오토노믹스 메디컬) is a development-stage medical device company focused on precision nerve-targeted therapies. The Company’s platform offers real-time, intra-procedural nerve mapping and radiofrequency (RF) ablation via a catheter-based microchip sensing array.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| AMIX | NASDAQ | 1.0825 | +48.90 | 7,051,044 |
Corporate Structure
Headquartered in The Woodlands, Texas, Autonomix Medical employs between 2 and 10 staff. The leadership team has over 80 years of combined experience in the medical device field:
- Brad Hauser, President and Chief Executive Officer, previously led device launches that resulted in acquisitions by AbbVie (RESONIC) and Boston Scientific (Watchman™).
- Jennifer Cook, Chief Business Officer, has developed go-to-market strategies for aesthetic and endoscopy devices at various companies, including Soliton and Apollo Endosurgery.
- Dr. Robert Schwartz, Chief Medical Officer, is a co-inventor of the Watchman™ device and has extensive experience in medical device innovation.
The Company’s global intellectual-property portfolio includes 18 patent families with over 120 issued or pending applications.
Nerve mapping by Google DeepMind
Recent Developments
- October 6, 2025: Filed a prospectus (Rule 424(b)(3)) in connection with an equity offering, outlining the use of proceeds and risk factors.
- October 23–26, 2025: Presented the abstract “Pain Mitigation in Pancreatic Adenocarcinoma...” at the Business of Pain: The Next Big Thing Annual Conference in Miami, FL.
- October 25–28, 2025: Participated in the Transcatheter Cardiovascular Therapeutics (TCT®) Annual Conference in San Francisco, CA, presenting first-in-human proof-of-concept data.
- October 30, 2025: Submitted a Current Report (Form 8-K) regarding corporate governance and executive updates.
- November 3, 2025: Filed an additional Form 8-K (items 5.07 and 9.01) detailing amendments to equity compensation plans and the appointment of financial advisors.
- November 12, 2025: Filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, outlining financial results and management’s discussion and analysis.
In September 2025, the Company expanded its first-in-human proof-of-concept study (PoC 1) in pancreatic cancer pain to a follow-on Phase 2 (PoC 2) cohort, with a focus on additional visceral cancers through celiac plexus denervation.
Financial and Strategic Analysis
According to public filings and market data:
- As of November 17, 2025, Autonomix held approximately $8.6 million in cash and cash equivalents.
- The trailing twelve-month net loss was approximately $12.05 million, with a diluted EPS of –5.33.
- Levered free cash flow for the same period was –$4.82 million.
- Market capitalization is approximately $7 million.
Strategically, the Company is focused on:
- Advancing its precision denervation platform across oncology, cardiology, pulmonology, and gastroenterology.
- Expanding PoC 2 to validate efficacy in multiple visceral cancer-pain indications.
- Preparing for U.S. pivotal trials based on insights from ongoing clinical studies.
Market Position and Industry Context
Autonomix operates within the medical device sector focused on the peripheral nervous system. Its technology provides nerve-mapping sensitivity that exceeds traditional approaches and facilitates transvascular treatment in various areas of the body. Key addressable markets include:
- Oncology pain management (initial focus on pancreatic, gall bladder, liver, and bile duct cancers)
- Cardiology and hypertension (renal denervation)
- Interventional pain management (non-cancer chronic pain)
The platform's capability to "sense, treat and verify" nerve activity intra-procedurally distinguishes it from competitors who rely on imaging or single-site ablation.
tl;dr
On November 17, 2025, AMIX shares traded at $1.0825 (+48.90%) on volume of 7.05 million. The Company filed its Q3 2025 Form 10-Q on November 12, reporting $8.6 million in cash and a trailing twelve-month net loss of $12.05 million. In late October, Autonomix presented PoC 1 clinical data at TCT® 2025 (October 27) and the Business of Pain conference (October 23–26), while advancing the study into PoC 2 covering additional visceral cancer-pain indications. Preparations are ongoing for planned U.S. pivotal trials.